Leap Therapeutics, an immuno-oncology company, recently reversed merge with Macrocure to become a publicly traded company, and received an investment of $10MM from current investors in order to advance two antibodies – DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein on cancer cells, and TRX518, a humanized GITR agonist that augments T-cell responses against tumors. Continue reading
Tag Archives: checkpoint control
DNAtrix and Merck Phase II Collaboration of Oncolytic Virus + Keytruda for Glioblastoma
DNAtrix and Merck announced a collaboration to combine oncolytic virus therapy and PD-1 inhibition – the two companies will collaborate in phase II clinical trials on a therapy to treat glioblastoma, an especially deadly cancer for which there is no cure. Continue reading
Nivolumab Phase 3 study stopped early for efficacy
Great news – nivolumab, BMS’ PD-1 immune checkpoint control inhibitor was shown to prolong overall survival when used front-line in patients with advanced melanoma. The study was stopped early, that is before it fully enrolled the planned number of patients, by an independent data monitoring committee because it was shown to be quite effective. Continue reading